P515: LOWER-INTENSITY CPX-351 + VENETOCLAX FOR PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA WHO ARE UNFIT FOR INTENSIVE CHEMOTHERAPY

P515: LOWER-INTENSITY CPX-351 + VENETOCLAX FOR PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA WHO ARE UNFIT FOR INTENSIVE CHEMOTHERAPY

Bibliographic Details
Main Authors:	G. L. Uy, V. A. Pullarkat, P. Baratam, R. K. Stuart, R. B. Walter, E. S. Winer, S. Faderl, V. Chandrasekaran, Q. Wang, D. Chakravarthy, R. S. Cheung, T. L. Lin
Format:	Article
Language:	English
Published:	Wiley 2022-06-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/01.HS9.0000844948.28359.0b

Similar Items

P514: V-FAST MASTER TRIAL: PRELIMINARY RESULTS OF TREATMENT WITH CPX-351 PLUS MIDOSTAURIN IN ADULTS WITH NEWLY DIAGNOSED FLT3-MUTATED ACUTE MYELOID LEUKEMIA
by: J. McCloskey, et al.
Published: (2022-06-01)

CPX-351 in FLT3-mutated acute myeloid leukemia
by: Claire Andrews, et al.
Published: (2023-11-01)

Quality-adjusted Time Without Symptoms of disease or Toxicity (Q-TWiST) analysis of CPX-351 versus 7 + 3 in older adults with newly diagnosed high-risk/secondary AML
by: Jorge E. Cortes, et al.
Published: (2021-07-01)

P516: CARDIOTOXICITY OF CPX-351 VS 7 + 3 IN PATIENTS WITH UNTREATED HIGH-RISK ACUTE MYELOID LEUKEMIA
by: Joshua D. Mitchell, et al.
Published: (2023-08-01)

PB1886: REAL WORLD EXPERIENCE OF VENETOCLAX-AZACYTIDINE COMBINATION IN FRAIL ELDERLY PATIENTS UNFIT FOR INTENSIVE CHEMOTHERAPY
by: Muhammad Naim Bin Che Rahimi, et al.
Published: (2023-08-01)

CPX-351 Pharmacokinetics and Safety in Adults with Hematologic Malignancies and Renal Function Impairment: Phase 1 Trial
by: Scott R. Solomon, et al.
Published: (2024-02-01)

FIVE-YEAR FINAL RESULTS OF A PHASE 3 STUDY OF CPX-351 VERSUS 7+3 IN OLDER ADULTS WITH NEWLY DIAGNOSED HIGH-RISK/SECONDARY ACUTE MYELOID LEUKEMIA (AML)
by: J.E. Lancet, et al.
Published: (2020-11-01)

MRD negative CR after azacitidine and venetoclax in a young patient with AML, unfit for intensive induction followed by ASCT
by: Deepak Kumar Shukla, et al.
Published: (2021-01-01)

Efficacy and safety of CPX-351 versus 7 + 3 chemotherapy by European LeukemiaNet 2017 risk subgroups in older adults with newly diagnosed, high-risk/secondary AML: post hoc analysis of a randomized, phase 3 trial
by: Jorge E. Cortes, et al.
Published: (2022-10-01)

PB1857: VENETOCLAX, AZACITIDINE, COMBINED WITH LOW-DOSE CYTARABINE IN OLDERLY OR UNFIT PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA
by: Xiao Han, et al.
Published: (2023-08-01)

Efficacy of venetoclax combined with hypomethylating agents in young, and unfit patients with newly diagnosed core binding factor acute myeloid leukemia
by: Keyuan Zhang, et al.
Published: (2023-10-01)

CPX-351: An Old Scheme with a New Formulation in the Treatment of High-Risk AML
by: Matteo Molica, et al.
Published: (2022-06-01)

CPX‐351 (Vyxeos®) can cause severe rash in acute myeloid leukemia—A case report
by: Ruth M. Urbantat, et al.
Published: (2021-04-01)

Real-world experience of CPX-351 as first-line treatment for patients with acute myeloid leukemia
by: Christina Rautenberg, et al.
Published: (2021-10-01)

Venetoclax combinations delay the time to deterioration of HRQoL in unfit patients with acute myeloid leukemia
by: Keith W. Pratz, et al.
Published: (2022-04-01)

PB1860: HIGH EFFICACY OF HYPOMETHYLATING AGENTS PLUS VENETOCLAX COMBINATION THERAPY IN ELDERLY PATIENTS AML PATIENTS UNFIT FOR INTENSIVE CHEMOTHERAPY: A REAL-LIFE EXPERIENCE.
by: Maria Elena Zannier, et al.
Published: (2023-08-01)

Venetoclax for the treatment of newly diagnosed acute myeloid leukemia in patients who are ineligible for intensive chemotherapy
by: Guillaume Richard-Carpentier, et al.
Published: (2019-10-01)

P574: CPX-351 COMBINED WITH HEMATOPOIETIC CELL TRANSPLANTATION WITH REGULATORY AND CONVENTIONAL T CELL IMMUNOTHERAPY FOR HIGH-RISK ACUTE MYELOID LEUKEMIA
by: S. Sciabolacci, et al.
Published: (2022-06-01)

P581: PHASE II STUDY OF LOWER-INTENSITY FRONTLINE THERAPY FOR NEWLY DIAGNOSED PATIENTS WITH AML WHO ARE UNFIT OR OTHERWISE NOT ELIGIBLE FOR FRONTLINE CLINICAL TRIALS
by: S. Venugopal, et al.
Published: (2022-06-01)

CPX-351: a nanoscale liposomal co-formulation of daunorubicin and cytarabine with unique biodistribution and tumor cell uptake properties
by: Mayer LD, et al.
Published: (2019-05-01)

Case Report: Allogeneic Stem Cell Transplantation Following Induction With CPX-351 in Patients With Acute Myeloid Leukemia Is Feasible
by: Vladan Vucinic, et al.
Published: (2020-09-01)

Venetoclax Plus Azacitidine as a Bridge Treatment to Allogeneic Stem Cell Transplantation in Unfit Patients with Acute Myeloid Leukemia
by: Tzu-Ting Chen, et al.
Published: (2024-03-01)

Single-Center Retrospective Clinical Evaluation of Venetoclax Combined with HMAs and Half-Dose CAG for Unfit or Refractory/Relapsed AML
by: Chen X, et al.
Published: (2023-06-01)

The successful combination of grapefruit juice and venetoclax in an unfit acute myeloid leukemia patient with adverse risk: A case report
by: Zhangbiao Long, et al.
Published: (2022-09-01)

Hypomethylating agent and venetoclax with FLT3 inhibitor “triplet” therapy in older/unfit patients with FLT3 mutated AML
by: Musa Yilmaz, et al.
Published: (2022-05-01)

P486: REAL-WORLD EFFECTIVENESS AND SAFETY OF CPX-351 IN PATIENTS AGED <60 AND ≥60 YEARS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA: CREST-UK POST-HOC ANALYSIS
by: Priyanka Mehta, et al.
Published: (2023-08-01)

P535: UPDATES FROM ITALIAN MULTICENTER REAL-LIFE EXPERIENCE ON CPX-351 THERAPY IN YOUNG PATIENTS (<60 YEARS OLD).
by: B. Garibaldi, et al.
Published: (2022-06-01)

Lower cardiotoxicity of CPX-351 relative to daunorubicin plus cytarabine free-drug combination in hiPSC-derived cardiomyocytes in vitro
by: Marie C. Fortin, et al.
Published: (2023-11-01)

CPX-351 (Vyxeos™) treatment in blast-phase myeloproliferative neoplasm (MPN-BP): real-world experience in 12 consecutive cases
by: Rimal Ilyas, et al.
Published: (2023-02-01)

P508: REAL LIFE EXPERIENCE USING FRONT-LINE CPX-351 FOR THERAPY-RELATED AND AML-MRC: RESULTS FROM THE SPANISH PETHEMA REGISTRY.
by: T. Bernal, et al.
Published: (2022-06-01)

S128: A RANDOMISED COMPARISON OF CPX-351 AND FLAG-IDA IN HIGH RISK ACUTE MYELOID LEUKAEMIA. RESULTS FROM THE NCRI AML19 TRIAL
by: N. Russell, et al.
Published: (2022-06-01)

Detection of the newly characterized HIV CRF56_cpx in Marseille, southeastern France
by: Philippe Colson, et al.
Published: (2014-12-01)

P513: CPX-351 TREATMENT FOR ACUTE MYELOID LEUKEMIA IN ENGLAND: REAL-WORLD OUTCOMES IN ADULTS AGED <60 YEARS VERSUS ≥60 YEARS
by: A. Legg, et al.
Published: (2022-06-01)

Venetoclax-containing regimens in acute myeloid leukemia
by: Ibrahim Aldoss, et al.
Published: (2021-02-01)

Dose Intensive Rituximab and High-Dose Methylprednisolone in Elderly or Unfit Patients with Relapsed Chronic Lymphocytic Leukemia
by: Regina Pileckyte, et al.
Published: (2019-10-01)

PB1763: THE CELLULAR UPTAKE OF CPX-351 BY SCAVENGER RECEPTOR CLASS B TYPE 1-MEDIATED NONENDOCYTIC PATHWAY IN LEUKEMIA CELLS.
by: Hiroaki Araie, et al.
Published: (2023-08-01)

Multicenter Observational Retrospective Study on Febrile Events in Patients with Acute Myeloid Leukemia Treated with Cpx-351 in “Real-Life”: The SEIFEM Experience
by: Luana Fianchi, et al.
Published: (2023-07-01)

P539: PROGNOSTIC RELEVANCE OF MINIMAL RESIDUAL DISEASE IN THERAPY RELATED AND SECONDARY ACUTE MYELOID LEUKEMIA RECEIVING CPX-351 OR FLUDARABINE-BASED INDUCTION.
by: F. Guolo, et al.
Published: (2022-06-01)

P517: PROSPECTIVE MULTICENTRIC STUDY ON INFECTIOUS COMPLICATIONS AND CLINICAL OUTCOME IN 230 UNFIT AML PATIENTS TREATED IN FIRST-LINE WITH HYPOMETHYLATING AGENTS ALONE OR IN COMBINATION WITH VENETOCLAX.
by: A. Candoni, et al.
Published: (2022-06-01)

PB1905: REAL-WORLD EXPERIENCE OF LOW-DOSE VENETOCLAX WITH AZACITIDINE FOR UNFIT AML PATIENTS(≥60Y) WITH LOW LEUKOCYTE COUNT
by: Wenjian Wei, et al.
Published: (2023-08-01)